Heterodimeric Antibodies for CD3 and CD38 Binding
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing bispecific antibodies face challenges such as biophysical and pharmacokinetic hurdles, particularly when engaging co-target antigens multivalently, leading to nonspecific activation and potential toxicity, especially in treating hematopoietic malignancies like non-Hodgkin's lymphoma and multiple myeloma.
Innovation Solution
Development of heterodimeric antibodies comprising monomers with specific amino acid substitutions and domain linkers to covalently attach variable and constant domains, allowing monovalent binding to CD3 and CD38, thereby reducing nonspecific activation and enhancing therapeutic efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If bispecific antibodies engage co-target antigens multivalently, then binding affinity is improved, but nonspecific activation and toxicity increase
Solution Approach 1:
The patent segments the bivalent binding function into two separate monovalent binding sites. Each antibody chain is engineered to bind only one antigen (CD3 or CD38) with a single binding site, eliminating the risk of nonspecific cross-linking while maintaining high affinity through optimized monovalent interactions.
Solution Approach 2:
The patent applies local quality by creating asymmetric antibody structures where different regions have specialized functions. The Fc region maintains standard effector functions while the Fab regions are engineered with specific monovalent binding characteristics, allowing localized optimization of binding properties without affecting overall antibody stability.
2Ease of manufacture
If antibody fragments are used to create bispecifics, then manufacturing ease and penetration are improved, but stability and half-life are reduced
Solution Approach 1:
The patent merges the advantages of antibody fragments (ease of manufacture, small size) with full-length antibodies (stability, long half-life). The engineered antibodies retain the complete IgG structure with Fc regions for stability and FcRn binding, while incorporating simplified variable region designs that ease manufacturing and improve tissue penetration.
3Stability of the object's composition
If full length antibody-like formats are used, then stability and half-life are improved, but bivalent binding leads to nonspecific activation
Solution Approach 1:
The patent introduces asymmetry by engineering antibodies where only one chain carries the antigen-binding variable regions while the other chain serves primarily as a stabilizing scaffold. This asymmetric design ensures monovalent binding geometry, preventing the symmetric bivalent cross-linking that causes nonspecific activation, while the complete Fc region maintains stability and half-life.
4Adaptability or versatility
If new variable regions are introduced for bispecific generation, then antigen binding diversity is improved, but manufacturing complexity increases
Solution Approach 1:
The patent employs dynamic design strategies where the antibody structure can accommodate different antigen specificities through modular variable region exchange. The standardized Fc and constant regions provide a stable platform that simplifies manufacturing, while the variable regions can be dynamically adjusted to target different antigen combinations without requiring complete redesign of the manufacturing process.
Data Source
AI summary
The present invention is directed to novel heterodimeric antibodies.